Related references
Note: Only part of the references are listed.Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2012)
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Michaela J. Higgins et al.
CLINICAL CANCER RESEARCH (2012)
Cancer Genomics: Technology, Discovery, and Translation
Ben Tran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Considerations in the development of circulating tumor cell technology for clinical use
David R. Parkinson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy
Monica Arnedos et al.
MOLECULAR ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients With Advanced Solid Tumors?
James H. Doroshow
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From Theoretical Synergy to Clinical Supra-Additive Toxicity
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
